Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Debt Repayments (2020 - 2022)

Neurocrine Biosciences' Long-Term Debt Repayments history spans 3 years, with the latest figure at $279.0 million for Q2 2022.

  • For Q2 2022, Long-Term Debt Repayments changed N/A year-over-year to $279.0 million; the TTM value through Sep 2023 reached $279.0 million, changed 0.0%, while the annual FY2024 figure was $308.8 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $279.0 million in Q2 2022 per NBIX's latest filing, up from $100000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $279.0 million in Q2 2022 to a low of $100000.0 in Q1 2021.
  • Average Long-Term Debt Repayments over 3 years is $155.3 million, with a median of $186.9 million recorded in 2020.